Skip to main content
SpringerLink
Log in

Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Type 2 diabetes mellitus and heart failure are closely related, patients with type 2 diabetes mellitus have a higher risk of developing heart failure, and those with heart failure are at increased risk of developing type 2 diabetes. Although no specific randomized clinical trials have been conducted to test the effect of cardiovascular therapies (drugs and/or devices) in diabetic patients with heart failure, a lot of evidence shows that all interventions effective in improving prognosis in patients with heart failure reduced ejection fraction are equally beneficial in patients with and without diabetes. However, the use of disease-modifying drugs in patients with diabetes and heart failure reduced ejection fraction is a clinical challenge due to the increased risk of adverse effects. For example, β-blockers are underutilized in diabetic patients due to the theoretical unfavorable effects on glucose metabolism as well as the use of drugs that interact with the renin-angiotensin system can be challenged in patients with diabetic nephropathy because of the risk of hyperkalemia. This review outlines the current use of disease-modifying drugs in diabetic patients with heart failure reduced ejection fraction. In addition, the role of novel pharmacologic agents as type 2 sodium-glucose co-transporter inhibitors (SGLT2ii) is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Metra M, Teerlink JR (2017) Heart failure. Lancet (London, England) 390:1981–1995. https://doi.org/10.1016/S0140-6736(17)31071-1

    Article  PubMed  Google Scholar 

  2. Murphy SP, Ibrahim NE, Januzzi JL Jr (2020) Heart failure with reduced ejection fraction: a review. JAMA 324:488–504. https://doi.org/10.1001/jama.2020.10262

    Article  PubMed  Google Scholar 

  3. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, Hu FB, Kahn CR, Raz I, Shulman GI, Simonson DC, Testa MA, Weiss R (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1:15019. https://doi.org/10.1038/nrdp.2015.19

    Article  PubMed  Google Scholar 

  4. Kaul U, Ray S, Prabhakar D, Kochar A, Sharma K, Hazra PK, Chandra S, Solanki D, Dutta AL, Kumar V, Rao MS, Oomman A, Dani S, Pinto B, Raghu TR (2020) Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Fail Rev. https://doi.org/10.1007/s10741-020-09955-7

    Article  Google Scholar 

  5. Dillmann WH (2019) Diabetic Cardiomyopathy. Circ Res 124:1160–1162. https://doi.org/10.1161/CIRCRESAHA.118.314665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wilkinson MJ, Zadourian A, Taub PR (2019) Heart failure and diabetes mellitus: defining the problem and exploring the interrelationship. Am J Cardiol 124:S3–S11. https://doi.org/10.1016/j.amjcard.2019.10.024

    Article  CAS  PubMed  Google Scholar 

  7. Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Med 130:S40–S50. https://doi.org/10.1016/j.amjmed.2017.04.010

    Article  CAS  PubMed  Google Scholar 

  8. Shaw JA, Cooper ME (2020) Contemporary management of heart failure in patients with diabetes. Diabetes Care 43:2895–2903. https://doi.org/10.2337/dc20-2173

    Article  CAS  PubMed  Google Scholar 

  9. Naegele M, Flammer AJ, Enseleit F, Ruschitzka F (2016) Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss Med Wkly 146:14295. https://doi.org/10.4414/smw.2016.14295

    Article  CAS  Google Scholar 

  10. Ge Z, Li A, McNamara J, Dos Remedios C, Lal S (2019) Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies. Heart Fail Rev 24:743–758. https://doi.org/10.1007/s10741-019-09806-0

    Article  PubMed  Google Scholar 

  11. Shearer F, Lang CC, Struthers AD (2013) Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin Pharmacol Ther 94:459–467. https://doi.org/10.1038/clpt.2013.135

    Article  CAS  PubMed  Google Scholar 

  12. Kishi T (2012) Heart failure as an autonomic nervous system dysfunction. J Cardiol 59:117–122. https://doi.org/10.1016/j.jjcc.2011.12.006

    Article  PubMed  Google Scholar 

  13. Tanai E, Frantz S (2015) Pathophysiology of heart failure. Compr Physiol 6:187–214. https://doi.org/10.1002/cphy.c140055

    Article  PubMed  Google Scholar 

  14. Savinova OV, Gerdes AM (2012) Myocyte changes in heart failure. Heart Fail Clin 8:1–6. https://doi.org/10.1016/j.hfc.2011.08.004

    Article  PubMed  Google Scholar 

  15. Frangogiannis NG (2019) The extracellular matrix in ischemic and nonischemic heart failure. Circ Res 125:117–146. https://doi.org/10.1161/CIRCRESAHA.119.311148

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Dirkx E, da Costa Martins PA, De Windt LJ (2013) Regulation of fetal gene expression in heart failure. Biochem Biophys Acta 1832:2414–2424. https://doi.org/10.1016/j.bbadis.2013.07.023

    Article  CAS  PubMed  Google Scholar 

  17. Poole-Wilson PA (2003) ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Med Clin North Am 87:373–389. https://doi.org/10.1016/s0025-7125(02)00174-8

    Article  CAS  PubMed  Google Scholar 

  18. Erhardt LR (2005) A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. Int J Clin Pract 59:571–578. https://doi.org/10.1111/j.1368-5031.2005.00513.x

    Article  CAS  PubMed  Google Scholar 

  19. Klapholz M (2009) Beta-blocker use for the stages of heart failure. Mayo Clin Proc 84:718–729. https://doi.org/10.4065/84.8.718

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Pitt B, Pedro Ferreira J, Zannad F (2017) Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. Eur Heart J Cardiovasc Pharmacother 31:48–57. https://doi.org/10.1093/ehjcvp/pvw016

    Article  Google Scholar 

  21. Khder Y, Shi V, McMurray J, Lefkowitz MP (2017) Sacubitril/valsartan (LCZ696) in heart failure. Handb Exp Pharmacol 243:133–165. https://doi.org/10.1007/164_2016_77

    Article  CAS  PubMed  Google Scholar 

  22. Custodio JS Jr, Duraes AR, Abreu M, Albuquerque Rocha N, Roever L (2018) SGLT2 inhibition and heart failure-current concepts. Heart Fail Rev 23:409–418. https://doi.org/10.1007/s10741-018-9703-2

    Article  CAS  PubMed  Google Scholar 

  23. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England) 396:819–829. https://doi.org/10.1016/S0140-6736(20)31824-9

    Article  PubMed  Google Scholar 

  24. Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ (2019) Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol 15:275–285. https://doi.org/10.1080/17425255.2019.1588886

    Article  CAS  PubMed  Google Scholar 

  25. Lopaschuk GD, Verma S (2020) Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. J Am Coll Cardiol Basic Trans Science 5:632–644. https://doi.org/10.1016/j.jacbts.2020.02.004

    Article  Google Scholar 

  26. Cruickshank JM (2002) Beta-blockers and diabetes: the bad guys come good. Cardiovasc Drugs Ther 16:457–470. https://doi.org/10.1023/a:1022146721098

    Article  CAS  PubMed  Google Scholar 

  27. Mills GA, Horn JR (1985) Beta-blockers and glucose control. Drug Intell Clin Pharm 19:246–251. https://doi.org/10.1177/106002808501900401

    Article  CAS  PubMed  Google Scholar 

  28. Ozyıldız AG, Eroglu S, Bal U, Atar I, Okyay K, Muderrisoglu H (2017) Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J Cardiovasc Pharmacol Ther 22:65–70. https://doi.org/10.1177/1074248416644987

    Article  CAS  PubMed  Google Scholar 

  29. Sanon VP, Sanon S, Kanakia R, Yu H, Araj F, Oliveros R, Chilton R (2014) Hypoglycemia from a cardiologist’s perspective. Clin Cardiol 37:499–504. https://doi.org/10.1002/clc.22288

    Article  PubMed  PubMed Central  Google Scholar 

  30. Nandish S, Wyatt J, Oliveros R, Zion AS, Lujan M, Chilton R (2010) A cardiologist’s view of hypoglycemia. Curr Atheroscler Rep 12:88–95. https://doi.org/10.1007/s11883-010-0093-8

    Article  CAS  PubMed  Google Scholar 

  31. Giles TD (2002) Use of beta-blockers for heart failure in patients with diabetes mellitus. Postgrad Med 112:32–37. https://doi.org/10.3810/pgm.11.2002.suppl22.118

    Article  PubMed  Google Scholar 

  32. Effect of metoprolol CR/XL in chronic heart failure (1999) Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001–2007

  33. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J, MERIT-HF Study Group (2005) Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 149:159–167. https://doi.org/10.1016/j.ahj.2004.05.056

    Article  CAS  Google Scholar 

  34. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529–1538. https://doi.org/10.1016/s0735-1097(03)00262-6

    Article  CAS  PubMed  Google Scholar 

  35. Haas SJ, Vos T, Gilbert RE, Krum H (2003) Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146:848–853. https://doi.org/10.1016/S0002-8703(03)00403-4

    Article  CAS  PubMed  Google Scholar 

  36. Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM (2012) Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 11:14. https://doi.org/10.1186/1475-2840-11-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Masarone D, Martucci ML, Errigo V, Pacileo G (2021) The use of β-blockers in heart failure with reduced ejection fraction. J Cardiovasc Dev Dis 8(9):101. https://doi.org/10.3390/jcdd8090101

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:137–161. https://doi.org/10.1161/CIR.0000000000000509

    Article  Google Scholar 

  39. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, Document Reviewers (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975. https://doi.org/10.1002/ejhf.592

  40. Investigators SOLVD, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302. https://doi.org/10.1056/NEJM199108013250501

    Article  Google Scholar 

  41. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown Jr. EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327(10):669–677. https://doi.org/10.1056/NEJM199209033271001

  42. Swedberg K, Kjekshus J (1988) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 62(2):60A-66A. https://doi.org/10.1016/s0002-9149(88)80087-0

    Article  CAS  PubMed  Google Scholar 

  43. Carson P, Johnson G, Fletcher R, Cohn J (1996) Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III. Drugs 47(Suppl 4):47–57; discussion 57–8. https://doi.org/10.2165/00003495-199400474-00008

  44. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342(3):145–153. https://doi.org/10.1056/NEJM200001203420301

    Article  Google Scholar 

  45. Gerstein HC (2002) Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 18:82–85. https://doi.org/10.1002/dmrr.285

    Article  CAS  Google Scholar 

  46. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:670–1676. https://doi.org/10.1056/NEJM199512213332503

    Article  Google Scholar 

  47. Peters DC, Noble S, Plosker GL (1998) Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs 56:871–893. https://doi.org/10.2165/00003495-199856050-00014

    Article  CAS  PubMed  Google Scholar 

  48. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K, Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110:2618–2626. https://doi.org/10.1161/01.CIR.0000146819.43235.A9

    Article  CAS  Google Scholar 

  49. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ, Investigators CHARM (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385. https://doi.org/10.1093/eurheartj/ehn153

    Article  PubMed  Google Scholar 

  50. Cohn JN, Tognoni G (2001) Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345(23):1667–75. https://doi.org/10.1056/NEJMoa010713

  51. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA (2009) HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 374:1840–1848. https://doi.org/10.1016/S0140-6736(09)61913-9.

  52. Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, Zannad F, Neaton JD, Konstam MA (2012) Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Fail 14:1401–1409. https://doi.org/10.1093/eurjhf/hfs145

    Article  CAS  PubMed  Google Scholar 

  53. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717.https://doi.org/10.1056/NEJM199909023411001

  54. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21. https://doi.org/10.1056/NEJMoa1009492

    Article  Google Scholar 

  55. Dojki FK, Bakris G (2017) Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens 26:368–374. https://doi.org/10.1097/MNH.0000000000000340

    Article  CAS  PubMed  Google Scholar 

  56. Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS (2020) Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep 22:140. https://doi.org/10.1007/s11886-020-01399-7

    Article  PubMed  Google Scholar 

  57. Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37:2105–2114. https://doi.org/10.1093/eurheartj/ehw132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G (2020) FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219–2229. https://doi.org/10.1056/NEJMoa2025845

  59. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators PARADIGM-HF, Committees, (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004. https://doi.org/10.1056/NEJMoa1409077

    Article  CAS  PubMed  Google Scholar 

  60. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray J, Solomon SD (2017) Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5:333–340. https://doi.org/10.1016/S2213-8587(17)30087-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Seferovic JP, Solomon SD, Seely EW (2020) Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab 11:2042018820970444. https://doi.org/10.1177/2042018820970444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Khan MS, Felker GM, Piña IL, Camacho A, Bapat D, Ibrahim NE, Maisel AS, Prescott MF, Ward JH, Solomon SD, Januzzi JL, Butler J (2021) Reverse cardiac remodeling following initiation of sacubitril/valsartan in patients with heart failure with and without diabetes. JACC Heart failure 9:137–145. https://doi.org/10.1016/j.jchf.2020.09.014

    Article  PubMed  Google Scholar 

  63. Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 6(7):547–554. https://doi.org/10.1016/S2213-8587(18)30100-1

    Article  CAS  PubMed  Google Scholar 

  64. Ferrari F, Martins VM, Scheffel RS, da Silveira AD, Motta MT, Moriguchi EH, Santos RD, Stein R (2021) The role of sodium-glucose cotransporter-2 inhibitors in patients with heart failure, regardless of diabetes status: focus on cardiovascular disease. Ann Pharmacother 1060028020985111. Advance online publication. https://doi.org/10.1177/1060028020985111

  65. Starr JA, Pinner NA, Lisenby KM, Osmonson A (2021) Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Pharmacotherapy. https://doi.org/10.1002/phar.2527

    Article  PubMed  Google Scholar 

  66. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators EMPA-REGOUTCOME (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720

    Article  CAS  PubMed  Google Scholar 

  67. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925

    Article  Google Scholar 

  68. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS (2019) DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389

  69. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK (2020) VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967

  70. McMurray J, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JGDAPA-HF, Committees T, Investigators, (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303

    Article  CAS  PubMed  Google Scholar 

  71. Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 42(36):3727–3738. https://doi.org/10.1093/eurheartj/ehab560

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323(14):1353–1368. https://doi.org/10.1001/jama.2020.1906

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, EMPEROR-Reduced Trial Investigators, (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424. https://doi.org/10.1056/NEJMoa2022190

    Article  CAS  PubMed  Google Scholar 

  74. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 143(6):516–525. https://doi.org/10.1161/CIRCULATIONAHA.120.052186

    Article  CAS  PubMed  Google Scholar 

  75. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368.

Download references

Author information

Authors and Affiliations

  1. Heart Failure Unit, Department of Cardiology, AORN Dei Colli-Monaldi Hospital, Via Leonardo Bianchi 1, 80100, Naples, Italy

    Daniele Masarone, Roberta Pacileo & Giuseppe Pacileo

Authors
  1. Daniele Masarone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberta Pacileo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Pacileo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniele Masarone.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masarone, D., Pacileo, R. & Pacileo, G. Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. Heart Fail Rev 28, 657–665 (2023). https://doi.org/10.1007/s10741-021-10189-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-021-10189-4

Keywords

Search

Navigation